Skip to content

Reducing Pacemaker Implantation After TAVR With Modified Implantation Technique

Reducing Pacemaker Implantation After TAVR With Modified Implantation Technique

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04734392
Acronym
MIDAS - ULM
Enrollment
300
Registered
2021-02-02
Start date
2020-01-01
Completion date
2023-11-28
Last updated
2023-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PM Implantation After TAVR

Brief summary

Hypothesis of the study is that a modified and improved implantation protocol (regarding membranous septum length and implantation depth) will decrease the need for permanent pacemaker stimulation follow TAVR-procedures.

Detailed description

Project objectives or hypothesis Hypothesis of the study is that a modified and improved implantation protocol (regarding membranous septum length and implantation depth) will decrease the need for permanent pacemaker stimulation following TAVR-procedures. Patient profile and sample size The study cohort will comprise of patients referred to transcatheter aortic valve replacement. Patients will be prospectively and consecutively screened and enrolled at a tertiary high-volume center in Germany. TAVR will be performed according to a modified implantation technique regarding membranous septum length. Pacemaker rates will be analyzed and compared to a historical control. Taking into account a contemporary pacemaker rate of 15%, a reduction to 7% will require a sample size of 239 patients per group to achieve statistically significance (Chi-squared test, alpha 0.05, beta 0.80). Regarding the prospective cohort, interims analysis will be performed after each 10 TAVR procedures. In case a signal towards worse outcomes with the modified implantation technique will be observed, the institutional safety and endpoint adjudication committee will stop further execution of the study.

Interventions

PROCEDURETAVR

TAVR implantation in cusp overlay technique

Sponsors

University of Ulm
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients referred to TAVR procedure due to severe aortic stenosis

Exclusion criteria

* PM-implantation before TAVR * Valve-in-valve procedures

Design outcomes

Primary

MeasureTime frameDescription
Pacemaker implantation rateDay 5 after TAVRPrimary endpoint

Secondary

MeasureTime frameDescription
Extent of paravalvular leakDay 5 after TAVRSecondary endpoint
Number of patients alive30 daysSecondary endpoint

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026